122675-28-9

Upstream product

• 38344-08-0 17-Phenyl-18,19,20-trinor-PGF(2α) 
• 74-88-4 methyl iodide 
• 41639-71-8 (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)hept-5-enoic acid 

Downstream Products

• 474326-89-1 methyl ester of tri(tert-butyldimethylsilyl)bimatoprost acid 
• 1163135-92-9 (5Z)-N-ethyl-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-5-phenyl-1-pentenyl]-cyclopentyl]hept-5-enamide 

Relevant academic research and scientific papers

Bimatoprost crystalline form I

The invention provides a novel polymorphic form I of crystalline bimatoprost, method for preparation thereof and new crystalline intermediates in the preparation. This form I of crystalline bimatoprost is used in purification of crude bimatoprost and in storage of bimatoprost as active pharmaceutical intermediate. Use of the physical form of bimatoprost in the manufacture of a medicament is also disclosed.

Method for preparing prostaglandin F analogue

A method for preparing a prostaglandin F analogue represented by the following formula (I) is disclosed, wherein R1, and are as defined in the specification.